Aim: To evaluate whether clinical genomic sequencing may benefit Chinese patients with stage IV cancer. Patients & methods: Chinese patients with cancer and their oncologists were provided with genomic sequencing results and corresponding clinical treatment recommendations based on evidence-based medicine, defined as CWES (clinical whole-exome sequencing) analysis. Chinese patients with stage IV cancer who failed the previous treatment upon receiving the CWES reports were included for analyzing the impact of CWES on clinical outcomes in 1-year follow-ups. Results: A total of 88.6% of 953 Chinese patients with cancer had clinically actionable somatic genomic alterations. Eleven patients followed the CWES reports, and 11 patients did not follow the CWES suggestions. The median progression-free survival of two groups were 12 and 4 months, and 45 and 91% of patients failed this round of therapy, respectively. Conclusion: The current study suggested that CWES has the potential to increase clinical benefits for Chinese patients with stage IV cancer.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Litton JK, Rugo HS, Ettl J et al. Talazoparib in patients with advanced breast cancer and a Germline BRCA mutation. N. Engl. J. Med. 379(8), 753–763 (2018).
Medline CASGoogle Scholar
2 Abou-Alfa, Ghassan K, Tim Meyer et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized Phase III CELESTIAL trial', 36: 207-07. J. Clin. Oncol. 36(4 suppl.), 207 (2018).
Google Scholar
3 Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018).
Medline CASGoogle Scholar
4 Gandhi L, Rodríguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).
Medline CASGoogle Scholar
5 Silva PJ, Schaibley VM, Ramos KS. Academic medical centers as innovation ecosystems to address population -omics challenges in precision medicine. J. Transl. Med. 16(1), 28 (2018).
Medline CASGoogle Scholar
6 Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin. Cancer Res. 23(15), 4242 (2017). • Shows the mechanism of hyperprogression after immunotherapy.
Medline CASGoogle Scholar
7 Tsimberidou AM, Wen S, Hong DS et al. Personalized medicine for patients with advanced cancer in the Phase I program at MD Anderson: validation and landmark analyses. Clin. Cancer Res. 20(18), 4827–4836 (2014).
Medline CASGoogle Scholar
8 Takeda M, Sakai K, Terashima M et al. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann. Oncol. 26(12), 2477–2482 (2015).
Medline CASGoogle Scholar
9 van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends Genet. 30(9), 418–426 (2014).
Medline CASGoogle Scholar
10 Santos R, Ursu O, Gaulton A et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16(1), 19–34 (2017). •• Presents an updated comprehensive map of molecular targets of approved drugs.
Medline CASGoogle Scholar
11 Yost SE, Smith EN, Schwab RB et al. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Nucleic Acids Res. 40(14), e107–e107 (2012).
Medline CASGoogle Scholar
12 Sathirapongsasuti JF, Lee H, Horst BAJ et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27(19), 2648–2654 (2011).
Medline CASGoogle Scholar
13 Li MM, Datto M, Duncavage EJ et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19(1), 4–23 (2017). •• Provides annotation, interpretation, and reporting conventions for somatic sequence variants.
Medline CASGoogle Scholar
14 Chalmers ZR, Connelly CF, Fabrizio D et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9(1), 34 (2017). • Shows the landscape of tumor mutational burden of 100,000 human cancer genomes.
MedlineGoogle Scholar
15 Peters S, Creelan B, Hellmann MD et al. Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026. Cancer Res. 77(13 Suppl.), CT082–CT082 (2017).
Google Scholar
16 Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med. 22(11), 1342 (2016).
Medline CASGoogle Scholar
17 Niu B, Ye K, Zhang Q et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30(7), 1015–1016 (2013).
MedlineGoogle Scholar
18 Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115 (2016).
MedlineGoogle Scholar
19 Kou T, Kanai M, Yamamoto Y et al. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci. 108(7), 1440–1446 (2017). •• Shows implementation of clinical sequencing using an next-generation sequencing (NSG)-based multiplex gene assay was feasible in the clinical setting.
Medline CASGoogle Scholar
20 Signorovitch J, Janku F, Wheler JJ et al. Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study. J. Clini. Oncol. 35(15_suppl.), 6605 (2017).
Google Scholar
21 Le TC, Delord JP, Gonçalves A et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled Phase 2 trial. Lancet Oncol. 16(13), 1324–1334 (2015).
MedlineGoogle Scholar
22 Massard C, Michiels S, Ferté C et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 7(6), 586 (2017). •• Suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers.
Medline CASGoogle Scholar
23 Mody RJ, Wu YM, Lonigro RJ et al. Integrative clinical sequencing in the management of children and young adults with refractory or relapsed cancer. JAMA 314(9), 913–925 (2015).
Medline CASGoogle Scholar
24 Astolfi A, Urbini M, Indio V et al. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics 16, 892–892 (2015).
MedlineGoogle Scholar
25 Bonnet E, Moutet M-L, Baulard C et al. Performance comparison of three DNA extraction kits on human whole-exome data from formalin-fixed paraffin-embedded normal and tumor samples. PLoS ONE 13(4), e0195471–e0195471 (2018).
MedlineGoogle Scholar
26 Zehir A, Benayed R, Shah RH et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23(6), 703–713 (2017). •• This reference compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations.
Medline CASGoogle Scholar
27 Schwaederle M, Parker BA, Schwab RB et al. Precision oncology: The UC San Diego Moores Cancer Center PREDICT experience. Mol. Cancer Ther. 15(4), 743–752 (2016). •• Reports their experience with using NGS and matching patients to therapy in a cohort of 347 patients with diverse, advanced solid tumors. They found that matching patients with drug targeting their genomic anomalies was associated with better outcome in multivariate analysis.
Medline CASGoogle Scholar
28 Mody RJ, Wu YM, Lonigro RJ et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314(9), 913–925 (2015).
Medline CASGoogle Scholar
29 Rubin MA. Health: Make precision medicine work for cancer care. Nature 520(7547), 290–291 (2015).
Medline CASGoogle Scholar
30 Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J. Clin. Oncol. 31(15), 1803–1805 (2013).
MedlineGoogle Scholar
31 Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ, Carpten JD. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4–ALK translocation as a therapeutic target. World J. Surg. 38(6), 1296–1305 (2014).
MedlineGoogle Scholar
32 Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5(1), 25–34 (2015).
Medline CASGoogle Scholar
33 Lawrence MS, Stojanov P, Mermel CH et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505(7484), 495–501 (2014).
Medline CASGoogle Scholar
34 Xue C, Hu Z, Jiang W et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 77(2), 371–375 (2012).
MedlineGoogle Scholar
35 Yatabe Y, Kerr KM, Utomo A et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J. Thorac. Oncol. 10(3), 438–445 (2015).
Medline CASGoogle Scholar
36 Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 20 (10), 1122–1130 (2018).
MedlineGoogle Scholar

Vol. 16, No. 4

Supplemental Materials

Metrics

Downloaded 160 times

History

Received 6 July 2018

Accepted 1 March 2019

Published online 21 March 2019

Published in print July 2019

Information

Keywords

Financial & competing interests disclosure

This study was supported by The National Key Research and Development Program of China (2016YFC0905402), National Natural Science Foundation of China (81372610) and the CSCO-Simcere Speclalized Research Fund for the Anti-tumor Treatment (Y-S2015-009). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

We obtained written informed consent from the donors for the use of genomic and clinical data for research purposes. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Acknowledgments

We gratefully acknowledge J Liu, N Zhang, F Wang, Z Liu, Y Wang, J Huang, X Wei, H Yang, P Huang, D Wang, B Yang, W Feng, Y Zhu, L Xue, S Xie, J Lu, H Li, G Yu, D Gu, J Chou and T Xu for their important contributions.

Author contributions

Q Xu, S Jiao and Y Bai contributed to the design and conduct of the study. S Jiao and Y Bai were responsible for the collection and analyses of clinical data. C Dai, X Cai and X Xu performed the experiments. G Wang and J Wei were responsible for bioinformatics and statistical analyses. B Wu and W Sun was responsible for writing the manuscript. All authors approved the final version of the manuscript.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/pme-2018-0056

PDF download

Using clinical genomic sequencing to guide personalized cancer therapy in China

Abstract

References